htb 121 hcc1419 atcc (ATCC)
ATCC is a verified supplier 
ATCC manufactures this product 
95
Structured Review
ATCC
htb 121 hcc1419 atcc
Htb 121 Hcc1419 Atcc, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 160 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/htb+121+hcc1419+atcc/BT-483/pm34525344-205-202-204
Average 95 stars, based on 160 article reviews
Htb 121 Hcc1419 Atcc, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 160 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/htb+121+hcc1419+atcc/BT-483/pm34525344-205-202-204
Average 95 stars, based on 160 article reviews
htb 121 hcc1419 atcc - by Bioz Stars,
2026-09
95/100 stars
Images
Related Articles
Drug discovery:Article Title: Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer. Article Snippet: Article Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer Transfection:Article Title: Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer. Article Snippet: Article Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer Membrane:Article Title: Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer. Article Snippet: Article Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer Flow Cytometry:Article Title: Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer. Article Snippet: Article Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer Activity Assay:Article Title: Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer. Article Snippet: Article Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer Viability Assay:Article Title: Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer. Article Snippet: Article Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer Gene Knockout:Article Title: Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer. Article Snippet: Article Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer Multiple Displacement Amplification:Article Title: Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer. Article Snippet: Article Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer Negative Control:Article Title: Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer. Article Snippet: Article Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer Recombinant:Article Title: Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer. Article Snippet: Article Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer |